Tumour budding as a prognostic biomarker in biopsies and resections of neoadjuvant‐treated rectal adenocarcinoma

Neoadjuvant Therapy Tumor budding
DOI: 10.1111/his.15192 Publication Date: 2024-04-17T09:54:26Z
ABSTRACT
Tumour budding (TB) is a marker of tumour aggressiveness which, when measured in rectal cancer resection specimens, predicts worse outcomes and response to neoadjuvant therapy. We investigated the utility TB assessment setting treatment.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (56)
CITATIONS (6)